VolitionRX Limited

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Volition RxLimited First Quarter 2024 Earnings Conference Call. During this presentation, all parties are in listen-only mode. Following the presentation, the conference call will be opened for questions. If you have a question, please press the star key followed by the number one on your touch-tone phone. If you would like to withdraw your question, Please press the star key followed by the number two. If you are using speaker equipment, please lift up the handset before making your selections. This conference call is being recorded today, May the 14th, 2024. I would now like to turn the conference over to Louise Batchelor, Group Chief Marketing and Communications Officer.

Please go ahead. Thank you.

and welcome everyone to today's earnings conference call for VolitionRx Ltd. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the Safe Harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs, as well as assumptions we have used, based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements may involve risks, uncertainties and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10 , quarterly reports on Form 10 , and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. We will start the call today with Terry Cuse, our Group Chief Financial Officer, who will cover Volition's financial and operating results for the first quarter of 2024, along with a discussion of recent finance activities and a look ahead. Dr. Andrew Retter, our recently appointed Chief Medical Officer, will provide a commentary about our clinical trial programme, and then Gael Forte, our Chief Commercial Officer, will summarise some of the key commercial achievements this quarter with a look ahead to upcoming milestones. Lastly, Cameron Reynolds, our President and Group Chief Executive Officer, will provide a brief wrap-up before we open the conference call to a question and answer session. I'll now turn the call over to Tereg.